The short version of phase 2 trial fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-18. Anything still debated is marked as such rather than presented as settled.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Snakes commonly involved in envenomations include elapids (such as kraits, cobras and mambas), vipers, and sea snakes. The majority of snake species do not have venom and kill their prey by constriction (squeezing them). Venomous snakes can be found on every continent except Antarctica. Determining the type of snake that caused a bite is often not possible. The World Health Organization says snakebites are a "neglected public health issue in many tropical and subtropical countries", and in 2017, the WHO categorized snakebite envenomation as a Neglected Tropical Disease (Category A). The WHO also estimates that between 4.5 and 5.4 million people are bitten each year, and of those figures, 40–50% develop some kind of clinical illness as a result. Furthermore, the death toll from such an injury could range between 80,000 and 130,000 people per year. The purpose was to encourage research, expand the accessibility of antivenoms, and improve snakebite management in "developing countries". Prevention of snake bites can involve wearing protective footwear, avoiding areas where snakes live, and not handling snakes. Treatment partly depends on the type of snake. Washing the wound with soap and water and holding the limb still is recommended. Trying to suck out the venom, cutting the wound with a knife, or using a tourniquet is not recommended. Antivenom is effective at preventing death from bites; however, antivenoms frequently have side effects. The type of antivenom needed depends on the type of snake involved.
The prolactin-releasing peptide receptor (PrRPR) also known as G-protein coupled receptor 10 (GPR10) is a protein that in humans is encoded by the PRLHR gene. PrRPR is a G-protein coupled receptor that binds the prolactin-releasing peptide (PRLH).
727.6 Rupture of tendon, nontraumatic 727.62 Rupture, biceps tendon 727.67 Rupture, achilles tendon 727.8 Other disorders of synovium, tendon, and bursa 727.83 Plica syndrome 727.89 Abscess, bursa 728 Disorders of muscle, ligament, and fascia 728.0 Infective myositis 728.1 Muscular calcification and ossification 728.2 Muscular wasting, atrophy 728.3 Other specific muscle disorders 728.4 Laxity of ligament 728.5 Hypermobility syndrome 728.6 Dupuytren's contracture 728.7 Other fibromatoses 728.71 Plantar fasciitis 728.8 Other disorders of muscle, ligament, and fascia 728.84 Diastasis recti 728.85 Muscle spasm 728.86 Necrotizing fasciitis 728.87 Muscle weakness 728.88 Rhabdomyolysis 728.89 Iliotibial band syndrome 729 Other disorders of soft tissues 729.0 Rheumatism unspecified and fibrositis 729.1 Myalgia and myositis, Fibromyositis 729.2 Neuralgia neuritis and radiculitis unspecified 729.3 Panniculitis unspecified 729.4 Fasciitis unspecified 729.5 Pain in limb 729.6 Foreign body in soft tissue 729.7 Nontraumatic compartment syndrome
== Contamination sources and removal == Bacteria, particles, organic carbon, ions, and dissolved gases are all present in typical municipal water systems and must be removed to create ultrapure water.
In August 2012, the viral advertising site "Dredd Report" was launched, satirising the Drudge Report. The site featured a video condemning the use of Slo-Mo, and links to news about the film. A tie-in comic book was published; its plot serves as a prequel to the film's narrative and follows Ma-Ma's life as a prostitute, controlled by her pimp Lester Grimes. Ma-Ma forms a relationship with Eric—the creator of Slo-Mo. Lester kills Eric for interfering with his business, Ma-Ma castrates Lester with her teeth in retaliation and Ma-Ma takes over the Slo-Mo operation. The comic was written by Judge Dredd Megazine editor Matt Smith, drawn by 2000 AD artist Henry Flint and was released on 5 September 2012. An exclusive film poster featuring artwork by Jock was released by Mondo to promote the film's appearance at the 2012 Fantastic Fest in September 2012. Dredd's marketing campaign won a Golden Trailer Award for Best Thriller TV Spot for the trailer "Big Addicted", and received nominations for: Best Action TV Spot, Most Original TV Spot, Best Graphics in a TV Spot, Best Music TV Spot, and Best Action Poster and Most Original Poster for the Dredd motion poster. Reports indicate that Lionsgate contributed $25 million to advertising and print costs. Dredd premiered at San Diego Comic-Con on 11 July 2012. It was also screened at the Toronto International Film Festival on 6 September, and at the Fantastic Fest in late September. The film was first theatrically released on 7 September in the UK and on 21 September worldwide. A South African release followed on 28 September.
Sources: en.wikipedia.org
These differences in newborn vocal fold composition would also be responsible for newborns inability to articulate sounds, besides the fact that their lamina propria is a uniform structure with no vocal ligament. The layered structure necessary for phonation will start to develop during the infancy and until the adolescence. The fibroblasts in the newborn Reinke's space are immature, showing an oval shape, and a large nucleus-cytoplasm ratio. The rough endoplasmic reticulum and Golgi apparatus, as shown by electron micrographs, are not well developed, indicating that the cells are in a resting phase. The collagenous and reticular fibers in the newborn the vocal cords are fewer than in the adult one, adding to the immaturity of the vocal fold tissue. In the infant, many fibrous components were seen to extend from the macula flava towards the Reinke's space. Fibronectin is very abundant in the Reinke's space of newborn and infant. Fibronectin is a glycoprotein that is believed to act as a template for the oriented deposition of the collagen fibers, stabilizing the collagen fibrils. Fibronectin also acts as a skeleton for the elastic tissue formation. Reticular and collagenous fibers were seen to run along the edges of the vocal cords throughout the entire lamina propria. Fibronectin in the Reinke's space appeared to guide those fibers and orient the fibril deposition. The elastic fibers remained sparse and immature during infancy, mostly made of microfibrils. The fibroblasts in the infant Reinke's space were still sparse but spindle-shaped.
Although Descartes agreed with the contemporary position, that a vacuum does not occur in nature, the success of his namesake coordinate system and more implicitly, the spatial–corporeal component of his metaphysics would come to define the philosophically modern notion of empty space as a quantified extension of volume. By the ancient definition however, directional information and magnitude were conceptually distinct.
It was fought to preserve Poland's independence and the nobility's traditional interests. After several years, it was brought under control by forces loyal to the king and those of the Russian Empire. Following the suppression of the Bar Confederation, parts of the Commonwealth were divided up among Prussia, Austria and Russia in 1772 at the instigation of Frederick the Great of Prussia, an action that became known as the First Partition of Poland: the outer provinces of the Commonwealth were seized by agreement among the country's three powerful neighbors and only a rump state remained. In 1773, the "Partition Sejm" ratified the partition under duress as a fait accompli. However, it also established the Commission of National Education, a pioneering in Europe education authority often called the world's first ministry of education.
Overall, Bagwell batted over .300 six times, had a career OBP of .408 (39th all-time), and had a slugging percentage of .540 (32nd all-time). He was elected to the Texas Sports Hall of Fame in 2005. In 2017, Bagwell was elected to the National Baseball Hall of Fame.
Sources: en.wikipedia.org
=== Valve === Faliszek's and Wolpaw's writings led to them being hired by Valve circa 2005. Along with Wolpaw and Marc Laidlaw, Faliszek helped to create the storylines for the Half-Life and Portal series, along with having personally written the story for Left 4 Dead. He was also involved with Valve's work in virtual reality (VR) through the HTC Vive. In May 2017, Faliszek announced that after twelve years with Valve, he had left the company earlier in the year to work on unannounced projects.
Orforglipron — brand name Foundayo — is an oral, non-peptide, small-molecule GLP-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company. It was discovered by Chugai Pharmaceutical Co., then was licensed to Lilly in 2018. Orforglipron was approved for medical use in the United States in April 2026. It was approved for use in the UK in August 2026.
The US Institute of Medicine (IOM) updated Estimated Average Requirements (EARs) and Recommended Dietary Allowances (RDAs) for B vitamins in 1998. At that time, there was not sufficient information to establish EARs and RDAs for pantothenic acid. In instances such as this, the Board sets Adequate Intakes (AIs), with the understanding that at some later date, AIs may be replaced by more exact information. The current AI for teens and adults ages 14 and up is 5 mg/day. This was based in part on the observation that for a typical diet, urinary excretion was approximately 2.6 mg/day, and that bioavailability of food-bound pantothenic acid was roughly 50%. AI for pregnancy is 6 mg/day. AI for lactation is 7 mg/day. For infants up to 12 months, the AI is 1.8 mg/day. For children ages 1–13 years, the AI increases with age from 2 to 4 mg/day. Collectively the EARs, RDAs, AIs and ULs are referred to as Dietary Reference Intakes (DRIs).
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.